Slide 1: Accuray – Euan Thomson, PhD, President & CEO
Accuray Euan Thomson, PhD President & CEO
Slide 2: Forward-looking Statement Safe Harbor Statement
Forward-looking Statement Safe Harbor Statement This presentation may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry and the transaction between Accuray and TomoTherapy. Except for the historical in
Slide 3: Radiation Therapy vs. Radiosurgery
Radiation Therapy vs. Radiosurgery Radiation Therapy Generally follows surgery Treats normal tissue surrounding tumor site Multiple treatments over several weeks Radiosurgery Replaces surgery Tumor ablation One to five treatments Accuray Confidential 4
Slide 4: Two best-in-class technologies for state of the art radiation therapy
RT IGRT/IMRT RS SBRT Gantry Linac Two best-in-class technologies designed for state of the art radiation therapy Gantry-based systems: Incremental evolution over 50 years RS Add-ons CyberKnife® Tomo Hi-Art Tomo HD Accuray Confidential 5
Slide 5: CyberKnife Platforms, Plans, Results
CyberKnife® Platforms, Plans, Results Accuray Confidential 6
Slide 6: CyberKnife system components
Linear Accelerator Manipulator Image Detectors X-ray Sources IMAGING SYSTEM ROBOTIC DELIVERY SYSTEM TARGETING SOFTWARE Accuray Confidential 7
Slide 7: CyberKnife Treatments
CyberKnife® Treatments Accuray Confidential 8
Slide 8: CyberKnife Treatments
CyberKnife® Treatments Accuray Confidential 9
Slide 9: CyberKnife Radiosurgery Market Acceptance
Liver CyberKnife® Radiosurgery Market Acceptance Patient Treatments Time Intracranial Inoperable Lung Prostate Partial Breast Operable Lung Spine Accuray Confidential 10
Slide 10: Clinical Development Worldwide Patient Treatments
Clinical Development Worldwide Patient Treatments This data includes estimates. If we are missing data from a site for one month, we take the number of patients treated in the previous month as an estimate for the missing month. If we are missing data from a site for a quarter (3 months), we take th
Slide 11: TomoTherapy Platforms, Plans, Results
TomoTherapy Platforms, Plans, Results Accuray Confidential 12
Slide 12: TomoTherapy Systems: Key differentiators
TomoTherapy Systems: Key differentiators Images Every Patient, Every Treatment, Every Day 3-D imaging is integral to treatment alignment Excellent image quality Helical IMRT Enables Highly Conformal Treatments Binary collimator and helical delivery Fully Integrated System One system designed for int
Slide 13: MLCs on Gantry Linacs have Limitations
MLC’s on Gantry Linacs have Limitations: Center of beam cannot be shielded using a single, “rapid arc” compromises must be made Accuray Confidential 14
Slide 14: MLCs on Gantry Linacs have Limitations
MLC’s on Gantry Linacs have Limitations: Accuray Confidential 15
Slide 15: Binary Collimator and Helical Delivery
Binary Collimator and Helical Delivery Alternative approach is “Binary Collimator” and helical delivery Patient moves through ring gantry Collimator rotates around patient Enables each volume element to be treated independently Accuray Confidential 16
Slide 16: Binary Collimator and Helical Delivery
Binary Collimator and Helical Delivery Courtesy of University of Virginia Accuray Confidential 17
Slide 17: Tomo HD Extends Range of Clinical Applications
Tomo HD Extends Range of Clinical Applications Tomo HD allows for advanced treatment plans of wide field regions while sculpting dose, creating complex dose patterns that minimize normal tissue included in the treatment field Accuray Confidential 18
Slide 18: Comparative Dose: Lund University Hospital
Comparative Dose Lund University Hospital – February 4th, 2011 TomoTherapy RapidArc Spinal Cord Accuray Confidential 19
Slide 19: Planned Acquisition
Planned Acquisition Accuray Confidential 20
Slide 20: Accuray Incorporated
Accuray Incorporated 200+ systems installed 100,000+ patients treated 75+ issued patents *as of March 31, 2011 Accuray Confidential 21
Slide 21: TomoTherapy Incorporated
TomoTherapy Incorporated Data provided by TomoTherapy 350 systems** 110,000+ patients treated 130+ issued patents **Shipped and/or installed as of February 17, 2011 *as of March 31, 2011 Accuray Confidential 22
Slide 22: IP Protection
IP Protection Accuray Patent Portfolio as of May 2011 Issued U.S. Patents 65 Pending U.S. Patent Applications 43 TomoTherapy Patent Portfolio as of Dec 2010 Issued U.S. Patents 41 Pending U.S. Patent Applications 40 Accuray Confidential 23
Slide 23: Milestones to Success
Milestones to Success TomoTherapy Service Improvement TomoTherapy service revenue will be incremental for Accuray but current service GM is negative TomoTherapy initiatives already showing improvements eg.“Fast-track” Accuray has additional expertise in linear accelerator technology Cost Saving Syne
Slide 24: Accuray Record of Achievement
Accuray Record of Achievement Consistent record of technology innovation Regular upgrades support premium service programs New CyberKnife® platforms support stronger pricing Proven ability to drive market acceptance New products New clinical capabilities Profitability Product gross profit margin (>6
Slide 25: Strategic Rationale
Strategic Rationale Complementary patient populations, treated by the same medical specialty Significant increase in global presence Financial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company
Slide 26: Accuray – Euan Thomson, PhD, President & CEO
Accuray Euan Thomson, PhD President & CEO